Zobrazeno 1 - 10
of 684
pro vyhledávání: '"D, Silberstein"'
Autor:
Michael A. Fishman, Ahish Chitneni, Alaa Abd-Elsayed, Samuel Grodofsky, Ashley M. Scherer, Brendan Schetzner, Malvina Klusek, Stephen R. Popielarski, Stephen Meloni, Steven Falowski, Philip Kim, Konstantin V. Slavin, Stephen D. Silberstein
Publikováno v:
Brain Sciences, Vol 13, Iss 12, p 1718 (2023)
Headache is a leading cause of disability and suffering. One major challenge in developing device treatments is demonstrating their efficacy given devices’ often-high placebo rate. This paper reviews the importance of validating sham devices as par
Externí odkaz:
https://doaj.org/article/9e98cc2da01f406698e86c3a48858664
Autor:
Stephen D. Silberstein, Joshua M. Cohen, Ronghua Yang, Sanjay K. Gandhi, Evelyn Du, Adelene E. Jann, Michael J. Marmura
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-11 (2021)
Abstract Background Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, including the fully humanized monoclonal antibody (IgG2Δa) fremanezumab, have demonstrated safety and efficacy for migraine prevention. Clinical
Externí odkaz:
https://doaj.org/article/ab5e628345ee4406a72f5bbf76a7d45d
Autor:
William B. Young, MD, Stephen D. Silberstein, MD, Stephanie J. Nahas, MD, Michael J. Marmura, MD
According to the National Headache Foundation, over 45 million Americans suffer from chronic, recurring headaches (28 million from migraine alone). Headache is the most common complaint for which people see neurologists. Headache can impede job funct
Autor:
Stephen D. Silberstein, Hans-Christoph Diener, David W. Dodick, Aubrey Manack Adams, Ronald E. DeGryse, Richard B. Lipton
Publikováno v:
Pain and Therapy, Vol 9, Iss 2, Pp 695-707 (2020)
Abstract Introduction The phase 3 PREEMPT trials demonstrated efficacy and tolerability of onabotulinumtoxinA for headache prevention in adults with chronic migraine. OnabotulinumtoxinA significantly reduced headache frequency from baseline vs. place
Externí odkaz:
https://doaj.org/article/ef98da12878347bd8fce948f3b33ed98
Autor:
Hans-Christoph Diener, David W. Dodick, Richard B. Lipton, Aubrey Manack Adams, Ronald E. DeGryse, Stephen D. Silberstein
Publikováno v:
Pain and Therapy, Vol 9, Iss 2, Pp 683-694 (2020)
Abstract Introduction The double-blind, phase 3 PREEMPT trials demonstrated the efficacy and tolerability of onabotulinumtoxinA for headache prevention in adults with chronic migraine. This post hoc analysis evaluated the effect of onabotulinumtoxinA
Externí odkaz:
https://doaj.org/article/419561ad40d04eef9c309aa4c24b6096
Autor:
Stephen D. Silberstein, Joshua M. Cohen, Michael J. Seminerio, Ronghua Yang, Sait Ashina, Zaza Katsarava
Publikováno v:
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background We evaluated the efficacy of fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, in patients with chronic migraine (CM) with and without medication overuse (MO). Methods In
Externí odkaz:
https://doaj.org/article/79e189a0224349308f684608a5e83c85
Autor:
Stephen D. Silberstein, Virginia L. Stauffer, Katie A. Day, Sarah Lipsius, Maria-Carmen Wilson
Publikováno v:
The Journal of Headache and Pain, Vol 20, Iss 1, Pp 1-11 (2019)
Abstract Background Patients with high-frequency episodic migraine (HFEM) have a greater disease burden than those with low-frequency episodic migraine (LFEM). Acute treatment overuse increases the risk of migraine chronification in patients with HFE
Externí odkaz:
https://doaj.org/article/6bf18bd9a86c4b099251d5825df9cc39
Publikováno v:
Expert Opinion on Pharmacotherapy. 24:617-627
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3153eef0e64f8335317a96382774ba25
https://doi.org/10.1080/14656566.2023.2194487
https://doi.org/10.1080/14656566.2023.2194487
Autor:
David W. Dodick, Anand S. Shewale, Richard B. Lipton, Seth J. Baum, Steven C. Marcus, Stephen D. Silberstein, Jelena M. Pavlovic, Nathan L. Bennett, William B. Young, Hema N. Viswanathan, Jalpa A. Doshi, Howard Weintraub
Publikováno v:
Journal of Primary Care & Community Health, Vol 11 (2020)
Introduction: Triptans, the most commonly prescribed acute treatments for migraine attacks are, per FDA labeling, contraindicated in cardiovascular (CV) disease patients and have warnings and precautions for those with CV risk factors. Methods: Heada
Externí odkaz:
https://doaj.org/article/415cffcf5f8d46a9abb0cffd6b3b36ef
Autor:
David Kudrow, Sagar Munjal, Leah Bensimon, Tasneem Lokhandwala, Binglin Yue, Anna D’Souza Coutinho, Stephen D Silberstein
Publikováno v:
Cephalalgia Reports, Vol 3 (2020)
Objective: To describe patient characteristics, treatment patterns, and health care costs among patients diagnosed with major headache disorders overall and by type (tension-type headache [TTH], migraine, cluster headache [CH], or >1 primary headache
Externí odkaz:
https://doaj.org/article/a905a97ae7444f239e28e95f49e53fda